David Spiegelhalter’s Gullible Skeptic, and a Bayesian “Hard-Nosed Skeptic” Reanalysis of the ANDROMEDA-SHOCK Trial

In a recent blog post, Bayesian icon David Spiegelhalter proposes a new analysis of the results from the ANDROMEDA-SHOCK randomized clinical trial. This trial was published in JAMA under the informative title “Effect of a Resuscitation Strategy Targeting Peripheral Perfusion Status vs Serum Lactate Levels on 28-Day Mortality Among Patients With Septic Shock”. In JAMA, …